111 related articles for article (PubMed ID: 8465126)
1. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
Graham S; Babayan RK; Lamm DL; Sawczuk I; Ross SD; Lavin PT; Osband ME; Krane RJ
Semin Urol; 1993 Feb; 11(1):27-34. PubMed ID: 8465126
[No Abstract] [Full Text] [Related]
2. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice.
Lavin PT; Maar R; Franklin M; Ross S; Martin J; Osband ME
Transplant Proc; 1992 Dec; 24(6):3059-64. PubMed ID: 1466057
[No Abstract] [Full Text] [Related]
3. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma.
Sawczuk IS
Urol Clin North Am; 1993 May; 20(2):297-301. PubMed ID: 8493751
[TBL] [Abstract][Full Text] [Related]
4. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
5. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Pierce WC; Belldegrun A; Figlin RA
Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
[No Abstract] [Full Text] [Related]
6. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma.
Osband ME; Lavin PT; Babayan RK; Graham S; Lamm DL; Parker B; Sawczuk I; Ross S; Krane RJ
Lancet; 1990 Apr; 335(8696):994-8. PubMed ID: 1970108
[TBL] [Abstract][Full Text] [Related]
7. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
8. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
9. [Biotherapy of advanced cancer by infusion of in vitro activated autolymphocytes].
Du X; Zhang M; Zhao M
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):464-6. PubMed ID: 8698005
[TBL] [Abstract][Full Text] [Related]
10. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
13. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
Litwin MS; Fine JT; Dorey F; Figlin RA; Belldegrun AS
J Urol; 1997 May; 157(5):1608-12. PubMed ID: 9112487
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study.
Ross S; Liu V; Abulafia R; Hogan C; Osband M
Biotechnol Ther; 1993; 4(3-4):197-211. PubMed ID: 7507387
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
Linehan WM; Walther MM; Alexander RB; Rosenberg SA
Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
[No Abstract] [Full Text] [Related]
19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
20. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
Otto U; Schneider AW; Conrad S; Klosterhalfen H
Prog Clin Biol Res; 1990; 350():275-82. PubMed ID: 2117287
[No Abstract] [Full Text] [Related]
[Next] [New Search]
